Are CB2 Receptors a New Target for Schizophrenia Treatment?
Schizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid system has also been associated with this disorder. Although initially described as present mostly in the periphery, cannabinoid type-2 (CB2) receptor...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-10-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2020.587154/full |
| _version_ | 1818872679690665984 |
|---|---|
| author | Isadora L. Cortez Naielly Rodrigues da Silva Francisco S. Guimarães Felipe V. Gomes |
| author_facet | Isadora L. Cortez Naielly Rodrigues da Silva Francisco S. Guimarães Felipe V. Gomes |
| author_sort | Isadora L. Cortez |
| collection | DOAJ |
| description | Schizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid system has also been associated with this disorder. Although initially described as present mostly in the periphery, cannabinoid type-2 (CB2) receptors are now proposed to play a role in several brain processes related to schizophrenia, such as modulation of dopaminergic neurotransmission, microglial activation, and neuroplastic changes induced by stress. Here, we reviewed studies describing the involvement of the CB2 receptor in these processes and their association with the pathophysiology of schizophrenia. Taken together, these pieces of evidence indicate that CB2 receptor may emerge as a new target for the development of antipsychotic drugs. |
| first_indexed | 2024-12-19T12:42:39Z |
| format | Article |
| id | doaj.art-0fb626e37ff0470e97259731394864dc |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-12-19T12:42:39Z |
| publishDate | 2020-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-0fb626e37ff0470e97259731394864dc2022-12-21T20:20:53ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402020-10-011110.3389/fpsyt.2020.587154587154Are CB2 Receptors a New Target for Schizophrenia Treatment?Isadora L. CortezNaielly Rodrigues da SilvaFrancisco S. GuimarãesFelipe V. GomesSchizophrenia is a complex disorder that involves several neurotransmitters such as dopamine, glutamate, and GABA. More recently, the endocannabinoid system has also been associated with this disorder. Although initially described as present mostly in the periphery, cannabinoid type-2 (CB2) receptors are now proposed to play a role in several brain processes related to schizophrenia, such as modulation of dopaminergic neurotransmission, microglial activation, and neuroplastic changes induced by stress. Here, we reviewed studies describing the involvement of the CB2 receptor in these processes and their association with the pathophysiology of schizophrenia. Taken together, these pieces of evidence indicate that CB2 receptor may emerge as a new target for the development of antipsychotic drugs.https://www.frontiersin.org/articles/10.3389/fpsyt.2020.587154/fullcannabinoidsendocannabinoid systempsychosisdopaminemicroglia |
| spellingShingle | Isadora L. Cortez Naielly Rodrigues da Silva Francisco S. Guimarães Felipe V. Gomes Are CB2 Receptors a New Target for Schizophrenia Treatment? Frontiers in Psychiatry cannabinoids endocannabinoid system psychosis dopamine microglia |
| title | Are CB2 Receptors a New Target for Schizophrenia Treatment? |
| title_full | Are CB2 Receptors a New Target for Schizophrenia Treatment? |
| title_fullStr | Are CB2 Receptors a New Target for Schizophrenia Treatment? |
| title_full_unstemmed | Are CB2 Receptors a New Target for Schizophrenia Treatment? |
| title_short | Are CB2 Receptors a New Target for Schizophrenia Treatment? |
| title_sort | are cb2 receptors a new target for schizophrenia treatment |
| topic | cannabinoids endocannabinoid system psychosis dopamine microglia |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2020.587154/full |
| work_keys_str_mv | AT isadoralcortez arecb2receptorsanewtargetforschizophreniatreatment AT naiellyrodriguesdasilva arecb2receptorsanewtargetforschizophreniatreatment AT franciscosguimaraes arecb2receptorsanewtargetforschizophreniatreatment AT felipevgomes arecb2receptorsanewtargetforschizophreniatreatment |